

Nanozyme, Inc.
Nanozyme designs and synthesizes disease specific nanoparticles that target and prevent viruses and diseased cells from replicating.
- Stage Product In Development
- Industry Biotechnology
- Location Orlando, FL, USA
- Currency USD
- Founded June 2013
- Employees 1
Company Summary
Nanozyme, Inc. is a spin-out from the University of Florida that develops synthetic nanomachines that can be programmed to only enter select diseased cells and targets only specified disease processes within those cells leaving healthy cells unharmed. The company's technology promises to decrease the cost of new drug discovery by a factor of 10 and can be tailored for wide range of virus and protein based disease states.
Team
-
Scott FarisCEO
Mr. Faris is a serial entrepreneur focused on physical and life science innovations. He currently serves as Founder and CEO of two Orlando based life science companies, MicroVapor Devices and Nanozyme, Inc. as well as the Board of Directors of Lightpath Technologies, Inc., Absolutely Natural, Inc. and is the Chairman of the Metro Orlando EDC. Mr. Faris was previously of several venture backed technology companies.
-
Charles CAOChief Science Officer
Dr. Charles Cao is a professor in the Department of Chemistry at the University of Florida, Gainesville. He is known for his work in the areas of nanocrystal synthesis, assembly, and surface functionalization. He has published over 44 papers and extensively in the Journal of the American Chemical Society and Angewandte Chemie.
-
Liu ChenChief Medical Officer
Dr. Chen Liu is a University of Florida professor; the director of the UF GI/Liver Pathology Fellowship; and the director of the Gastrointestinal and Liver Pathology Division at UF’s Department of Pathology. Dr. Liu is a well-established GI/liver pathologist and an NIH-funded liver disease investigator. Dr. Liu has also published more than 120 peer-reviewed articles and book chapters.
Advisors
-
Ed AlexanderLawyerUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.